索拉菲尼治疗晚期原发性肝癌的临床观察

Clinical observation of sorafenib monotherapy in patients with advanced primary liver cancer

目的观察索拉菲尼治疗晚期原发性肝癌的临床疗效及毒性反应。方法21例晚期原发性肝癌患者口服索拉菲尼400mg，每日2次，6周为1个周期，直至病情进展或出现不可耐受的毒性反应。治疗6周后评定疗效和安全性。结果21例患者均完成6周治疗，其中部分缓解4例，病情稳定10例，病情进展7例，中位疾病进展时间为5．2个月。治疗期间发生手足皮肤反应者19例，其中1级10例，2级8例，3级1例；腹泻1级6例；恶心、呕吐1级5例；乏力1级3例；皮疹1级3例，2级7例；脱发1级4例；高血压1级1例；口炎1级1例。结论索拉菲尼治疗晚期原发性肝癌可控制肿瘤生长，不良反应可以耐受。

Objective To observe the efficacy and side effects of sorafenib monotherapy in patients with advanced primary liver cancer. Methods All 21 patients with advanced primary liver cancer were treated by sorafenib 400 mg twice daily, and the efficacy and side effects of sorafenib monotherapy were evaluated after sorafenib treatment for 6 weeks. Results Of 21 patients, 4 patients achieved partial remission, 10 patients achieved stable disease, and 7 patients achieved progression of disease ; time to progress was 5.2 months. The main side effects： 19 cases occurred hand-foot skin reaction, and grade one, two and three was in 10, 8 and 1 case, respectively; diarrhea was in 6 cases, and all were grade one; 5 cases undertook nausea/vomiting, and all was grade one ; skin rash was in 10 cases, and the grade one was 3 cases, grade two was 7 cases ; 4 cases was baldness ; lack of power, stomatitis and hypertension was in 1 case respectively, and all were grade one. Conclusion Sorafenib monotherapy in advanced primary liver cancer can control the growth of tumor.